Longitudinal study on metabolic health in SGA adults during 5 years after GH with or without 2 years of GnRHa treatment.

Like Comment
In children born small for gestational age (SGA) with persistent short stature, 2 years of gonadotropin-releasing hormone analogue (GnRHa), in addition to long-term growth hormone (GH) treatment, can improve adult height. We assessed safety on metabolic and bone health of GnRHa/GH treatment during 5 years after cessation of GH.363 young adults born SGA, previously treated with combined GnRHa/GH or GH-only, were followed for 5 years after attainment of adult height: at GH-cessation, 2 and 5 years thereafter. Data at 5 years after GH-cessation, at age 21 years, were also compared to 145 age-matched adults born appropriate for gestational age (AGA). Frequently sampled intravenous glucose tolerance (FSIGT) tests were used to assess insulin-sensitivity, acute insulin response and β-cell function. Body composition and bone mineral density (BMD) was determined by DXA scans.In the GnRHa/GH and GH-only group, fat mass increased during the 5 years after GH cessation, but the changes in FSIGT results, body composition, blood pressure, serum lipid levels and BMD were similar in both groups. At age 21 years, the GnRHa/GH group had similar fat mass, FSIGT results, blood pressure, serum lipid levels and BMD-total body as the GH-only group and AGA controls, a higher BMD-lumbar spine and lower lean body mass than AGA controls.This study during 5 years after GH cessation shows that addition of 2 years of GnRHa treatment to long-term GH treatment of short children born SGA has no unfavorable effects on metabolic and bone health in early adulthood.

Click here to read the full article @ The Journal of clinical endocrinology and metabolism
Go to the profile of ClinOwl


The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
2311 Contributions
0 Following

No comments yet.